Plus   Neg

Cara Therapeutics Inc. (CARA) Is Surging In Early Trade

Cara Therapeutics Inc. (CARA) announced Wednesday morning that the Independent Data Monitoring Committee of its Phase 3 study of KORSUVA Injection has determined that no change needs to be made to the trial's enrollment target.

Cara Therapeutics has been rising sharply since the open of trade Wednesday and is now up 1.43 at $14.43. The stock has broken out to over a 1-week high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT